GlassScriptPhysician profile
Reuben Azad
NPI 1598104515
$8,506.61
in general payments reported to CMS, 2019-2025
33 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,662 · 2020: $361 · 2021: $1,817 · 2022: $1,918 · 2023: $859 · 2024: $470 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,111.47 | 2019-2023 | Optis, Dragonfly Opstar, Pressurewire |
| Impulse Dynamics (USA) INC. | $385.59 | 2021-2023 | Optimizer |
| Novartis Pharmaceuticals Corporation | $384.64 | 2019-2025 | |
| Astellas Pharma US INC | $372.99 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $326.27 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $200.51 | 2022-2024 | |
| Amgen INC. | $192.76 | 2022-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $171.10 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $153.70 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.76 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $130.51 | 2020-2025 | Camzyos |
| Pfizer INC. | $124.58 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $111.15 | 2022-2025 | Farxiga |
| Biosense Webster, INC. | $81.32 | 2022-2024 | Carto 3 |
| Scpharmaceuticals INC. | $79.13 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $74.19 | 2021 | |
| Edwards Lifesciences Corporation | $61.35 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biogen, INC. | $54.37 | 2024-2025 | Skyclarys |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.47 | 2022-2024 | Lifevest |
| Bardy Diagnostics, INC. | $30.00 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $29.20 | 2023 | Arcalyst |
| Siemens Medical Solutions USA, INC. | $28.24 | 2022 | |
| Esperion Therapeutics, INC. | $23.75 | 2023 | Nexletol |
| Heartflow, INC. | $22.53 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.13 | 2023 | Edarbi |
| Medicomp INC | $20.94 | 2025 | Telepatch Cardiac Monitor |
| Cook Medical LLC | $19.65 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.79 | 2023 | Amvuttra |
| Agepha Pharma Fz LLC | $17.34 | 2024 | Lodoco |
| Lantheus Medical Imaging, INC. | $16.62 | 2020 | |
| Abiomed | $16.42 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.10 | 2022 | |
| Amarin Pharma, INC. | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reuben Azad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.